文献速递质量管理与危急值临床生化

自动审核、发布与报告结果的验证及患者伤害风险评估:临床实验室流程算法提案

Verification of automated review, release and reporting of results with assessment of the risk of harm for patients: the procedure algorithm proposal for clinical laboratories.
PubMed 文献 · Clin Chem Lab Med · 2024-12-30

该研究基于实验室信息系统回顾性数据,由七名实验室医学专家对生化、粪便、尿液和全血检测的自动审核规则进行逐步验证,并采用失效模式与效应分析评估风险。共生成23,633份报告、246,579个结果,80.66%符合自动审核标准,假阴性率0.83%、假阳性率0.02%,风险优先数为0。结论认为自动审核与专家意见高度一致,对患者安全无显著风险,并首次提出逐步实施建议。

要点

  • 自动审核假阴性率0.83%,主要与中位数和差值检查值相关。
  • 自动审核假阳性率0.02%,所有病例风险优先数(RPN)为0。
  • 研究提出逐步验证算法,支持ISO 15189:2022的流程确认与风险评估。

核心结论

  • 自动审核与非自动审核结果与专家意见高度一致,分歧极小(分别为0.02%和0.83%)。
  • 风险分析显示自动审核对患者安全无显著风险。
  • 本研究首次提供实验室实施自动审核的逐步建议。

研究设计与样本

  • 回顾性研究,使用实验室信息系统数据,七名实验室医学专家参与。
  • 自动审核规则针对Alinity ci(Abbott)、Atellica 1500(Siemens)和ABL90 FLEX(Radiometer)上的血清、粪便、尿液和全血分析物定义。
  • 标准包括室内质控结果、仪器标志、溶血/黄疸/脂血指数、患者中位数、危急值、测量范围、差值检查和参考值。
  • 逐步验证,采用失效模式与效应分析计算风险优先数(RPN)。

主要发现

  • 共生成23,633份实验室报告,包含167项生化检测的246,579个结果。
  • 198,879个结果(80.66%)符合自动审核标准。
  • 2,057个结果(0.83%)专家不同意自动审核标准(假阴性),分歧主要与中位数和差值检查值相关。
  • 仅识别45个假阳性(0.02%),所有病例RPN为0。

关键数值与推荐

  • 自动审核符合率80.66%(198,879/246,579)。
  • 假阴性率0.83%(2,057个结果),假阳性率0.02%(45个结果)。
  • 所有假阳性病例风险优先数(RPN)为0。

临床怎么用

  • 实验室可参考本研究提出的逐步算法实施自动审核验证。
  • 验证应涵盖质控、仪器标志、指数、中位数、危急值、测量范围、差值检查和参考值等标准。
  • 应结合失效模式与效应分析评估自动审核的患者安全风险。

局限性

  • 研究为回顾性设计,使用单一实验室信息系统数据。
  • 仅七名专家参与,专家意见可能存在主观性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Autoverification increases the efficiency of laboratories. Laboratories accredited according to ISO 15189:2022 need to validate their processes, including autoverification, and assess the associated risks to patient safety. The aim of this study was to propose a systematic verification algorithm for autoverification and to assess its potential risks. METHODS: The study was conducted using retrospective data from the Laboratory Information System (LIS). Seven laboratory medicine specialists participated. Autoverification rules were defined for analytes in serum, stool, urine and whole blood determined on Alinity ci (Abbott), Atellica 1500 (Siemens) and ABL90 FLEX (Radiometer). Criteria included internal quality control results, instrument flags, hemolysis/icteria/lipemia indices, median patient values, critical values, measurement ranges, delta checks, and reference values. Verification was performed step by step. Risk analysis was performed using Failure Modes and Effects Analysis and the Risk Priority Number (RPN) was calculated. RESULTS: During the study, 23,633 laboratory reports were generated, containing 246,579 test results for 167 biochemical tests. Of these, 198,879 (80.66 %) met the criteria for autoverification. For 2,057 results (0.83 %), the experts disagreed with the autoverification criteria (false negatives). Discrepancies were mainly associated to median and delta check values. Only 45 false positives (0.02 %) were identified, resulting in an RPN of 0 for all cases. CONCLUSIONS: The autoverified and non-autoverified results showed high agreement with the expert opinions, with minimal disagreement (0.02 % and 0.83 %, respectively). The risk analysis showed that autoverification did not pose a significant risk to patient safety. This study, the first of its kind, provides step-by-step recommendations for implementing autoverification in laboratories.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Miler M, Nikolac Gabaj N, Šimić G, et al. Verification of automated review, release and reporting of results with assessment of the risk of harm for patients: the procedure algorithm proposal for clinical laboratories. Clin Chem Lab Med. 2024. PMID: 39733330. doi:10.1515/cclm-2024-1164

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。